Table 1 Baseline characteristics of treated patients.
ID Number | Gender | Age (years) | KPS (%) | HLA-A2 | LDH | Stage IV | Sites of Metastasis | Prior Cytokine Therapy | Prior Chemotherapy |
|---|---|---|---|---|---|---|---|---|---|
0001–1103 | M | 49 | 80 | + | 169 | M1b | Abdominal wall, thorax | IL2 | Yes |
0002–2101 | M | 30 | 90 | + | 130 | M1b | Lung | IL2 | No |
0002–2102 | F | 39 | 80 | + | 429 | M1c | Skin, lymph nodes, liver | IFNα2b | Yes |
0003–3101 | M | 44 | 90 | - | 575 | M1c | Skin, lymph nodes, lung | IL2 and IFNα2b | Yes |
0003–3102 | M | 67 | 80 | + | 1388 | M1c | Lymph nodes, skin, lung, liver | IL2 and IFNα2b | Yes |
0004–4101 | M | 40 | 100 | + | 132 | M1a | Skin | IFNα2b | No |
0004–4102 | M | 36 | 90 | + | 333 | M1c | Lymph nodes, spleen, liver | IFNα2b | Yes |
0004–4103 | F | 54 | 90 | - | 94 | M1c | Skin, liver | IFNα2b | No |
0004–4104 | M | 76 | 90 | - | 282 | M1c | Skin, lung | IFNα2b | No |